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Abstract
Mild stress can protect against a larger insult, a phenomenon termed preconditioning or tolerance. To determine if a low
intensity stressor could also protect cells against intense oxidative stress in a model of dopamine deficiency associated with
Parkinson disease, we used methamphetamine to provide a mild, preconditioning stress, 6-hydroxydopamine (6-OHDA) as a
source of potentially toxic oxidative stress, and MN9D cells as a model of dopamine neurons. We observed that prior
exposure to subtoxic concentrations of methamphetamine protected these cells against 6-OHDA toxicity, whereas higher
concentrations of methamphetamine exacerbated it. The protection by methamphetamine was accompanied by decreased
uptake of both [3H] dopamine and 6-OHDA into the cells, which may have accounted for some of the apparent protection.
However, a number of other effects of methamphetamine exposure suggest that the drug also affected basic cellular
survival mechanisms. First, although methamphetamine preconditioning decreased basal pERK1/2 and pAkt levels, it
enhanced the 6-OHDA-induced increase in these phosphokinases. Second, the apparent increase in pERK1/2 activity was
accompanied by increased pMEK1/2 levels and decreased activity of protein phosphatase 2. Third, methamphetamine
upregulated the pro-survival protein Bcl-2. Our results suggest that exposure to low concentrations of methamphetamine
cause a number of changes in dopamine cells, some of which result in a decrease in their vulnerability to subsequent
oxidative stress. These observations may provide insights into the development of new therapies for prevention or
treatment of PD.
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Introduction
Exposure of cells to subtoxic amounts of stress can provide
protection against normally toxic stress levels. This phenomenon,
referred to as preconditioning or tolerance, has been studied
primarily in models of ischemia [see [1,2] for reviews]. However,
related phenomena have been observed using a variety of stimuli,
including anesthetic agents [3], exercise [4],[5], dietary restriction
[6], hypothermia and hyperthermia [7], and low doses of toxins
[8],[9].
We are particularly interested in determinants of dopamine
(DA) neuron death. Loss of DA neurons projecting from the
substantia nigra to the striatum is a hallmark of Parkinson’s disease
(PD). Although the cause of this neurodegeneration is unknown,
evidence suggests that oxidative stress, mitochondrial dysfunction,
and accumulation of misfolded proteins are involved [10,11,
12,13]. Moreover, as in the case of ischemia, several observations
suggest that mild stress can be protective in models of PD. Thus,
for example, studies in animal models of the DA deficiency
associated with PD have indicated protective effects of dietary
restriction [14] thrombin preconditioning [15], exercise, forced
motor use, and environmental complexity [4,16,17].
In vitro studies further support the hypothesis that mild cellular
stress can protect cell lines exhibiting some aspects of the DA
phenotype. For example, pinacidil, xanthine/xanthine oxidase,
and FeSO4 have each been shown to protect PC12 cells against
concentrations of MPTP or rotenone, which would otherwise kill
the cells via inhibition of mitochondrial respiration [18,19,20].
Our group has reported that although 6-hydroxydopamine (6-
OHDA) is normally toxic to DA cells due to the formation of
reactive oxygen species (ROS) [20], exposure of the dopaminergic
cell line MN9D, which exhibits many dopaminergic properties
[21], to low concentrations of the neurotoxin protects against
higher concentrations [20]. Likewise, exposure of PC12 cells to
low concentrations of the proteasome inhibitor MG132 can
protect against a much larger insult [9].
In this report, we have chosen to study the impact of a single 24-
hr exposure of a stressor on the vulnerability of MN9D cells to
subsequent intense oxidative stress. For the conditioning stimulus
we have used methamphetamine (METH), which is toxic to DA
cells at least in part due to the formation of ROS [see reviews by
[22,23,24]. The challenge stress was 6-OHDA [25],[26]. Our
results show that 24 hr exposure to low concentrations of METH
protected the cells against subsequent exposure to 6-OHDA. This
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was associated with an increase in activated extracellular regulated
kinase (ERK) and an upregulation of the pro-survival protein Bcl-
2. Our results extend the evidence suggesting that exposure to mild
oxidative stress induces an upregulation of pro-survival molecules
and decreases vulnerability to a larger insult of the same or a
different nature.
Methods
Materials
Unless otherwise noted, all reagents were obtained from Sigma-
Aldrich Corporation, St. Louis, MO and were of the highest
available purity.
Cell Culture
The dopaminergic cell line MN9D was originally obtained
from Drs. Alfred Heller and Lisa Won (University of Chicago,
Chicago, IL) and are now available from our laboratory at the
University of Pittsburgh by arrangement with the University of
Chicago. The cells result from a fusion of rostral mesencephalic
neurons from embryonic C57BL/6J (E14) mice with the
N18TG2 neuroblastoma cells [21]. There are a number of
important similarities between these cells and DA neurons [21],
and we have found them be a valuable model for studies of the
DA deficiency associated with PD [20,27,28,29], as have many
others [e.g., [30],[31,32,33].
The cells were used in their undifferentiated form between
passage 8 and 20 and were plated in Primaria 10 cm plates (BD-
Falcon Biosciences, Bedford, MA) in Dulbecco’s Modified Eagle’s
Media (DMEM) (Gibco, Invitrogen Corp, Carlsbad, CA). The
media was supplemented with sodium bicarbonate and the pH
adjusted to 7.2 before adding 50 units/ml penicillin, 50 mg/ml
streptomycin, and, 10% fetal bovine serum (Hyclone, Logan, UT).
The cells were kept in an incubator at 37uC with 5% CO2.
Treatments
For viability experiments, MN9D cells were plated at 10,000
cells per well in triplicate in 96-well Primaria plates (BD, Franklin
Lakes, NJ), and all treatments were performed 24 hr after plating.
Unless otherwise noted, cells were incubated with METH (0–
3 mM) or vehicle (standard medium) for 6 or 24 hr in serum-
containing medium. The medium was then changed, and the cells
were washed with standard medium and treated with 100 mM 6-
OHDA for 20 min in a special medium as described below to
circumvent its degradation during short term treatments as
confirmed by HPLC. The 6-OHDA-containing medium was then
removed and the cells were incubated in fresh standard medium
for an additional 24 hr until assay. To avoid 6-OHDA breakdown
and formation of oxidation products, the drug was made in a
vehicle containing 0.15% ascorbic acid and the metal chelator
diethylenetriamine penta-acetic acid (DETAPAC, 10 mM) and
flushed for 10 min with nitrogen gas to further reduce oxidative
degradation of 6-OHDA [34]. Lighting conditions were also kept
minimal during treatment for the same reason. The effects of 6-
OHDA were always compared with the effects of its vehicle. When
the MAP kinase kinase (MEK1/2) inhibitor U0126 (Calbiochem,
EMD Chemicals Inc. San Diego, CA) was used, cells were
pretreated for 1 hr with 10 mM U0126 or its vehicle before and
during the time of 6-OHDA exposure. Because very little toxicity
was seen 6 hr post-METH treatments (data not shown) we chose
to use the 24 hr time point, which is the most common time point
used for in vitro studies looking at the effect of METH on cell
viability [35,36,37,38,39].
WST-1 assay
We used the WST-1 cell proliferation assay (Roche Applied
Science, Indianapolis, IN) to estimate the number of viable cells by
detecting the cleavage of tetrazolium salts by the mitochondrial
dehydrogenases, which is affected by the availability of NADH,
the redox status of the cell, and the presence of ROS. MN9D cells
were treated as described above, and 23 hr after treatment with 6-
OHDA the medium was removed and replaced with a fresh
medium containing the WST-1 reagent. Absorbance at 440 nm
was measured using an ELISA plate reader after 30 min incubation
at 37uC.
CellTiter-Glo assay
Another non-biased viability index used was the Cell Titer-Glo
luminescent assay. This assay is based on a luciferase/luciferin
reaction that, in the presence of Mg2+ and ATP, produces
oxyluciferin and releases energy in the form of luminescence. Since
the luciferase reaction requires ATP, the luminescence produced is
proportional to the amount of ATP present, an indicator of
cellular metabolic activity. We used the Cell Titer-Glo kit
(Promega, MA) according to the manufacturer instructions.
Briefly, the plate was taken from the incubator and brought to
room temperature, and 100 ml of Cell Titer-Glo mixture were
added to each well. The cells were then lysed by shaking the plate
at high speed for 10 min. After 10 min, we transferred 100 ml
from each well to another 96-well plate. The luminescence reading
was performed using a Vector 96-well plate reader (Perkin-Elmer,
Boston, MA).
Hoechst reagent assay
We used bisbenzimide (Hoechst 33258) to quantify nuclear
condensation in cells going into apoptosis. This reagent is
relatively selective for double stranded DNA and binds specifically
to the A-T base pairs in the DNA, resulting in an increase in
fluorescence. Twenty-four hr after 6-OHDA treatment, the
medium was removed, and the cells fixed using 100 ml of 4%
paraformaldehyde solution in 4% sucrose for 20 min. The fixation
solution was removed and replaced with 100 ml staining solution
(1 mg/ml Hoechst reagent) for another 20 min. The staining
solution was then taken out and replaced with 100 ml PBS with
0.01% azide and the cells were then stored at 4uC until analysis.
Photomicrographs of each well were taken at 206 using Meta-
Morph software (Molecular Devices, Downingtown, PA) with a
Nikon Inverted Eclipse microscope and the number of viable cells
counted while being blind to the treatment.
3H-DA uptake assay
The 3H-DA uptake assay was adapted from defazio et al., [40]
with some modifications. MN9D cells were treated with METH
for 24 hr. The media was then aspirated and the cells incubated
with 50 nM 3H-DA in PBS supplemented with 25 mM glucose,
1 mM CaCl2, and 1 mM MgCl2 for 15 min at 37uC. The specific
activity of this batch of 3H-DA was 59.3 Ci/mmol (American
Radiolabeled Chemicals, St. Louis, MO). Following 3 washes with
ice-cold supplemented PBS, 3H-DA was extracted from culture
twice using 0.1 N perchloric acid and 25% ethanol and added to
Cytoscint scintillation fluid (ICN, Costa Mesa, CA). The DA
uptake was measured using a liquid scintillation spectroscopy
(Beckman LS-1800; Beckman Coulter, Inc. Fullerton, CA). Non-
specific uptake was determined by adding the DA uptake inhibitor
nomifensine (10 nM) prior to and during the assay. In another set
of experiments, cells were treated with METH for 24 hr, the
media was changed and the cells incubated for 20 min with
METH Protection against 6-OHDA
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vehicle alone or vehicle plus 6-OHDA before performing the DA
uptake assay as described above.
Assay of 6-OHDA
HPLC coupled with electrochemical detection was used to
measure the amount of 6-OHDA taken up into MN9D cells using
minor modifications of previous methods [41,42]. After the
incubation was complete, the cells were collected by centrifugation,
washed, lysed in 0.1 N HClO4 containing 0.2 mM NaHSO3, and
an aliquot injected onto a ESA C18 column (2.16150 mm, ESA,
Inc., Chelmsford, MA). The mobile phase was pumped through the
system at 0.3 ml/min using a ESA LC-10AD pump (ESA Inc.,
Chelmsford, MA). Analytes were detected coulometrically using an
ESA Coulochem Model 4100A detector, an ESA Model 5010
conditioning cell, and an ESAModel 5014B microdialysis cell (ESA
Inc., Chelmsford, MA).
Western Blot analysis
MN9D cells were plated in 6-well plates at the density of
500,000 cells per well and lysates were collected at different times
points after treatment. Cells were washed with sterile chilled
Dulbecco’s phosphate buffer saline (DPBS) and then lysed with a
1% Triton X-100 lysis buffer containing 20 mM Tris (pH 6.8),
137 mM NaCl, 25 mM beta glycerophosphate, 2 mM NaPPi,
2 mM EDTA, 1 mM Na3VO4, 10% glycerol, 5 mg/ml leupeptin,
5 mg/ml aprotinin, 2 mM benzamidine, 0.5 mM DTT, and
1 mM PMSF. Cells were collected in ice cold lysis buffer and
lysed for 30 min before centrifugation at 4uC for 30 min at
15 000 g. Protein content was determined using the bicinchoninic
acid (BCA) assay (Pierce, Rockford, IL), and 20 mg protein from
each sample was separated on a 10% SDS gel and transferred to a
PVDF membrane (Bio-Rad labs, Hercules, CA). The blots were
then blocked in 5% non-fat milk and incubated overnight at 4uC
with primary antibodies. After washes, membranes were incubated
at room temperature for 60 min with diluted horseradish
peroxidase-conjugated anti-rabbit secondary antibody (1:10000;
Calbiochem, San Diego, CA). Bound antibody was visualized by
chemiluminescence (NEN, Boston, MA), and the blots were then
stripped and re-probed for total protein. Equal protein loading was
confirmed by probing for a-tubulin. Polyclonal antibodies were
purchased from cell signaling (Cell Signaling Technology,
Danvers, MA) and used at the following concentrations;
pERK1/2 (Thr202/Tyr204, Cat. no. 9101) at 1:1000; pMEK1/
2 (Ser217/221, Cat. no. 9121) at 1:1000; pAkt (Ser473, Cat. no
9271) at 1:200; pJNK (Thr183/Tyr185, Cat. no. 9251) at 1:200;
total ERK1/2 at 1:1000 (Cat. no. 9102); total MEK1/2 at 1:1000
(Cat. no. 9122); total Akt at 1:1000 (Cat. no 9271) and total JNK
at 1:200 (Cat. no. 9252). Antibodies for CuZnSOD and MnSOD
were from Upstate (Lake placid, NY) and were used at the
following concentrations: CuZnSOD at 1:250 (Cat. no. 07–403),
MnSOD at 1:600 (Cat. no. 06–984). Polyclonal rabbit anti-Bcl-2
was used at 1:200 (Cat. no. sc-4096 WB; Santa Cruz Biotechnol-
ogy; Santa Cruz, CA).
Protein phosphatase activity assay
Controls and cells treated with sub-lethal concentration of
METH were lysed in a lysis buffer containing 2 mM EDTA,
2 mM EGTA, and 20 mM Imidazole-HCl, pH 7.0. The lysis
buffer was supplemented with proteases inhibitors but not with
phosphatases inhibitors. The protein phosphatase 2 (PP2A)
immunoprecipitation and activity assays were performed using a
non-radioactive PP2A activity assay kit (Upstate Biotechnologies,
Lake Placid, NY). Following the manufacturer instructions, 500 mg
protein from each sample were incubated for 2 hr at 4uC with the
PP2A antibody 16D specific to the catalytic subunit (PP2Ac)
(Upstate Biotechnologies). The protein A-Sepharose beads (2 mg)
were then added to the lysates and the incubation continued
overnight. Cells were then washed with the Ser/Thr buffer and
equivalent immunoprecipitation of PP2A in all samples was con-
firmed by immunoblot with PP2Ac. Immunoprecipitated PP2A
was then tested for activity measuring dephosphorylation of the
phosphopeptide KRpTIRR spectrophotometrically at 650 nm
using the malachite green [43].
Statistical analysis
Statistical significance was determined using ANOVA (Graph
Pad, San Diego, CA) and the Student-t test for statistical com-
parisons between groups. Each experimental condition was repeated
in triplicate on at least 3 separate occasions. Data comparisons were
considered significant if the p-value was 0.05 or less.
Results
6-OHDA and METH caused cell death in concentration-
dependent manners
MN9D cell were exposed to medium containing 6-OHDA for
20 min, which was then replaced with standard growth medium,
and cell viability was assayed 24 hr later. We observed that 6-
OHDA decreased cell viability in a concentration-dependent
manner. At 100 mM, 6-OHDA reduced cell viability by
approximately 50% when assayed by Hoechst staining followed
by cell counts based on morphological change such as nuclear
condensation and staining intensity. At 500 mM 6-OHDA, MN9D
cell viability was reduced by 90% (data not shown) confirming
previous findings from our lab [28,29]. In addition, an EC50
comparable to that obtained with the Hoechst reagent was
obtained with the Cell Titer-Glo assay, which estimates cell
viability by measuring changes in ATP levels, and the WST-1
assay, which estimates cell density by measuring changes in
NADH activity (Fig. 1A). For all subsequent experiments we used
100 mM 6-OHDA in order to detect changes in cell viability when
pre-treating with METH.
Next, cells were exposed to METH for 24 hr and the decrease
in cell viability after an additional 24 hr was assessed. We observed
that the drug decreased basal cell viability in a concentration-
dependent manner with an EC50 between 2 and 3 mM, depending
on the assay used (Fig. 1B). We did not see any significant effect of
METH concentrations on cell viability at or below 1 mM with any
of the three viability assays used. From these observations, we
selected 0.5 and 1 mM METH as pretreatment concentrations for
preconditioning studies.
Pretreatment with low concentrations of METH
protected cells against 6-OHDA toxicity
MN9D cells were treated with METH for 24 hr. The METH-
containing medium was then removed and the cells exposed to
medium containing 6-OHDA for 20 min, after which it was
replaced with standard growth medium, and cell viability was
measured 24 hr later. As we had previously shown (Fig. 1B),
exposure of MN9D cells to 0.5 or 1.0 mM METH had no
significant effect on their viability as assessed by Cell Titer-Glo or
WST-1 assays. However, prior exposure of cells to these
concentrations of METH greatly reduced 6-OHDA-induced cell
death as measured by each of these methods (Fig. 2A, B, and C).
In contrast, no protection was seen with any of our assays when we
used higher concentrations of METH that were themselves toxic
(e.g., 3 mM). Indeed, the toxic effects of 6-OHDA were increased
by prior exposure to these high concentrations of METH (Fig. 2A
METH Protection against 6-OHDA
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and 2B). Morphological changes induced by 6-OHDA included
shrinkage of the cytoplasmic membrane and chromatin conden-
sation, which are consistent with an apoptotic form of cell death
(Fig. 2C).
METH inhibited the uptake of [3H] DA and the
accumulation of 6-OHDA
METH is known to reversibly interfere with the high affinity
DA transporter [44,45,46] Thus, one explanation for the METH-
induced tolerance towards 6-OHDA toxicity was that the drug
reduced the uptake of 6-OHDA into the MN9D cells. Several
experiments were performed to examine this possibility.
First, we measured 3H-DA uptake after 24 hr of exposure to
0.5 mM METH and then washed the cells with standard medium
without METH before incubation for 20 min with 6-OHDA, thus
precisely mimicking the protocol for our preconditioning exper-
iments. Under these conditions, METH-induced inhibition of DA
uptake was reduced to 38% (Fig. 3B), a sizable effect but a
significantly less than the impact of the same concentration of
METH on viability (Fig. 2). In contrast, 24 hr of incubation with
0.5 mM METH and without a wash before 6-OHDA decreased
DA uptake by 75% to 80% (p,0.01) (Fig. 3A).
Next, we measured the amount of 6-OHDA that accumulated
in MN9D cells pre-treated with 0.5 or 1 mM METH for 24 hr
Figure 1. METH and 6-OHDA induced toxicity in MN9D cells. (A) MN9D cells were treated with 6-OHDA for 20 min and viability assays
performed 24 hr after 6-OHDA removal. 6-OHDA killed MN9D cells in a concentration-dependent fashion with an EC50 of approximately 100 mM. (B)
MN9D Cells were treated with the indicated concentrations of METH for 24 hr and viability assays performed 24 hr later. METH affected ATP levels,
mitochondrial dehydrogenase activity, and chromatin condensation as assessed by Hoechst staining. The average EC50 for METH for the three
different viability assays was between 2 and 3 mM. Data represent means 6 SEM of 3–5 independent experiments. *P,0.05, ***p,0.001 compared
to controls.
doi:10.1371/journal.pone.0024722.g001
METH Protection against 6-OHDA
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using HPLC. We observed that METH reduced the accumulation
of 6-OHDA in a concentration- and time-dependent manner.
When cells were exposed to 0.5 or 1 mM METH, no significant
difference in 6-OHDA accumulation was observed at either 15 or
20 min, the time points at which we would normally stop 6-OHDA
treatment in our preconditioning experiments. In contrast, after
only 5 min of exposure to 6-OHDA, 1 mM (but not 0.5 mM)
METH reduced 6-OHDA accumulation by 55% (p,0.05) when
cells were preconditioned (Fig. 3C). Collectively, these results
suggest that METH pretreatment may have reduced 6-OHDA
toxicity in MN9D cells in part by an initial reduction in 6-OHDA
uptake, but that this reduction was relatively small and transient,
Figure 2. Sub-lethal concentrations of METH protected MN9D cells against 6-OHDA toxicity. Cells were treated with the indicated
concentrations of METH for 24 hr. The medium was then changed, the cells treated with 100 mM 6-OHDA for 20 min and viability assays performed
24 hr after 6-OHDA removal. Sub-toxic concentrations of METH protected ATP levels (A) and mitochondrial dehydrogenase activity (B), and prevented
chromatin condensation of Hoechst stained cells (C). The photomicrographs in Panel (C-I) show control cells lacking any sign of nuclear condensation
or chromatin clumping, In panel (C-II) MN9D cells have lifted off the plate after 6-OHDA exposure, presumably due to cell death. Arrows point to
dying cells with high chromatin condensation. In panel (C-III) METH pretreated cells were protected against 6-OHDA toxicity (C-III). Data represent
means 6 SEM (N= 3). *P,0.05 compared to 0 mM METH/100 mM 6-OHDA, #p,0.01compared to 0 mM METH/0 mM 6-OHDA.
doi:10.1371/journal.pone.0024722.g002
METH Protection against 6-OHDA
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Figure 3. METH affects dopamine transporter function. (A) MN9D cells were treated with different concentration of METH for 24 hr and 3H-DA
uptake assayed with METH still in the media as described in the methods section. (B) MN9D cells were treated with METH for 24 hr, the media was
changed, the cells were then treated with vehicle or 6-OHDA (100 mM) for 20 min, and DA uptake assayed immediately after. (C) MN9D cells were
METH Protection against 6-OHDA
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and thus not able to explain the preconditioning we observed. That
assumption was further supported by the additional experiments
that we will now describe.
METH decreased pERK1/2, but potentiated the
subsequent pERK1/2 response to 6-OHDA
To determine if METH also produced intracellular signaling
changes that might contribute to its ability to protect cells against 6-
OHDA, we looked at ERK, a member of the MAP kinase family
that has frequently been shown to promote cell survival. Changes in
the levels of the activated, phosphorylated form of ERK1/2 were
determined by Western blot analysis using a phospho-specific
ERK1/2 antibody. A low concentration of METH (0.5 mM) by
itself caused a marked decline in pERK1/2 that was prominent
after 15 min (Fig. 4A) and still detectable 24 hr after treatment
(Fig. 4B). Treatment with 6-OHDA alone induced a biphasic
increase in pERK1/2 that peaked at 15 min, returned to basal
levels by 1 hr, and subsequently decreased below basal levels by
24 hr (Fig. 4B, C). However, despite the possibility that METH
pretreatment may have decreased the uptake of 6-OHDA into the
MN9D cells (see above), pre-incubation with METH actually
caused a persistent increase in the levels of pERK1/2 normally seen
after 6-OHDA exposure (Fig. 4B, C). These same effects were seen
at all time points examined.
treated with METH for 24 hr, the media was changed and cells treated with 100 mM 6-OHDA or vehicle. The cells were collected at different time
points to analyze 6-OHDA content using HPLC-EC. Data are presented as means 6 SEM (N= 3). *p,0.05, **p,0.01 compared to 0 mM METH,
#p,0.05 compared to 0.5 mM METH.
doi:10.1371/journal.pone.0024722.g003
Figure 4. METH decreased basal pERK1/2 levels and potentiated ERK1/2 phosphorylation induced by 6-OHDA. (A) Western blot
analysis showing pERK levels at different time points after exposure to sub-lethal concentration of METH (0.5 mM) for up to 24 hr. Lysates were
collected at 15 min, 30 min, 1 hr, 6 hr, and 24 hr. Shown are the 15 min and 30 min time points. (B) pERK1/2 levels decreased by 15 min post METH
exposure and lasted for up to 24 hr. METH decreased activation of ERK 1/2 in a concentration-dependent manner (0, 0.5, and 1 mM at the 24 hr time
point) and enhanced the activation of ERK1/2 after 6-OHDA exposure. This activation lasted from 15 to at least 24 hr. (C) Quantification of ERK1/2
activation in response to 6-OHDA. (D) MN9D cells were treated with sub-lethal concentration of METH (0.5 mM) for 24 hr, the medium was removed
and the cells treated with the MEK1/2 inhibitor U0126 (10 mM) for 1 hr before and during the 20 min 6-OHDA exposure. Western blot analysis
confirmed the activation of ERK1/2 by 6-OHDA and its enhancement by METH preconditioning and confirmed that U0126 blocked the
phosphorylation of ERK1/2. (E) Viability assay looking at ATP levels and performed 24 hr post 6-OHDA treatment showed that METH protected MN9D
cells against 6-OHDA toxicity and U0126 abolishes this protection. a-tubulin was used as a loading control. Data are presented as means 6 SEM
(N= 3). *p,0.05, **p,0.01 compared to vehicle and #p,0.05 compared to lane 10.
doi:10.1371/journal.pone.0024722.g004
METH Protection against 6-OHDA
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Inhibition of ERK activation reduced the protective effect
of METH
MEK 1/2 is the upstream activator of ERK1/2. Thus, we used
the MEK1/2 inhibitor, U0126, to determine if the METH-
induced changes in pERK1/2 were related to the METH-
induced protection against 6-OHDA. Addition of U0126 (10 mM)
for 1 hr before and during exposure to 6-OHDA or its vehicle,
inhibited the activation of pERK1/2 due to METH and 6-
OHDA treatments with no change in total ERK1/2 pro-
tein (Fig. 4D). It also reduced the toxic effects of high con-
centrations of METH, though not of 6-OHDA (Fig. 4E).
Nevertheless, U0126 abolished the protection against 6-OHDA-
induced cell death that was provided by METH pretreatment.
Those effects were not seen when the cells were treated with the
U0126 vehicle.
Low concentration of METH increased MEK1/2 activation
in response to 6-OHDA
The previous experiment showed that inhibition of pERK1/2
activation blocked the protection by METH against 6-OHDA.
This suggested that pERK1/2 was somehow involved in METH-
induced preconditioning. To examine this further, we looked at
the effect of METH on MEK1/2. We observed that pMEK1/2,
like pERK1/2, was decreased by pretreatment with a low
concentration of METH (0.5 mM) (Fig. 5A). However, again as
in the case of pERK1/2, MEK1/2 phosphorylation was increased
by 6-OHDA treatment and this effect was potentiated by METH
preconditioning (Fig. 5A, B).
METH preconditioning decreased PP2A activity
The levels of pERK are determined by the opposing effects of
two phosphoproteins, pMEK, which increases pERK, and PP2A,
which decreases it. To determine PP2A activity after METH
preconditioning, we used a two-step assay comprised of PP2A
immunoprecipitation followed by quantification of its activity [43].
To ensure comparability, we first confirmed that equal amounts of
PP2A had been immunoprecipitated in control and METH
treated MN9D cells by using an antibody specific to the catalytic
subunit 1D6 (PP2Ac), and then measured the effect of METH
treatment on PP2A activity. We found that 24 hr exposure to 0.5–
3 mMMETH had no effect on PP2A protein levels, but decreased
PP2A activity in a concentration-dependent fashion.
METH preconditioning also enhanced the response of
pAkt but not pJNK to 6-OHDA
The serine/threonine-specific protein kinase Akt is another
common intracellular survival factor, and over-expression of
activated Akt has been shown to protect against METH toxicity
[47]. To ascertain whether the Akt pathway plays a role in METH
preconditioning against 6-OHDA toxicity, we examined changes
in Akt phosphorylation at residue Ser473, which is required for
Akt activity [48] and has been shown to be involved in
preconditioning [49]. As in the case of pERK, we found that
pAkt levels decreased in response to METH at 15 min and 30 min
and returned to baseline levels by 24 hr (Fig. 6A), However,
METH pretreatment for 24 hr enhanced Akt phosphorylation
seen 15 min after 6-OHDA insult (Fig. 6B,C).
Figure 5. METH preconditioning affected MEK1/2 and PP2A. (A) A representative blot showing that sublethal concentrations of METH
decreased the levels of pMEK1/2 and enhanced MEK1/2 activation induced by 6-OHDA. MN9D cells were treated with METH for 24 hr, the medium
was changed, and cells treated with 6-OHDA for 20 min. Lysates were collected at 0, 15 min, 60 min, and 24 hr post 6-OHDA treatment. (B)
Quantification of panel A in 4 independent experiments. (C) PP2A activity assay was performed as described in the methods section from cells treated
with various METH concentrations for 24 hr. METH pretreatment decreased PP2A activity in a concentration dependent manner, although total
cellular PP2A levels were not affected. *p,0.05, **p,0.01 compared to control.
doi:10.1371/journal.pone.0024722.g005
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In contrast to ERK and Akt, Jun N-terminal kinase (JNK) is
more commonly considered a pro-death signaling molecule. To
examine the role of JNK in our experimental paradigm, lysates
from control and METH-treated cells were assayed for phosphor-
ylated and total JNK. We observed that 24 hr exposure to a low
concentration of METH had no effect on pJNK levels. After 6-
OHDA incubation, we saw an activation of pJNK (mainly the
46 kDa immunoreactive band and not the 56 kDa band).
However, METH pretreatment did not affect the activation of
pJNK1 in response to 6-OHDA (Figure 6D). The immunoblot
depicting the effect of METH preconditioning on JNK1/2
activation also revealed the presence of a third immunoreactive
band with a molecular weight of approximately 42 kDa. This
band is likely to represent an interaction of the JNK antibody used
in our experiments with the pERK2 band, which also has a
molecular weight of 42 kDa, since this band disappeared when
pre-treating the cells with U0126 (Figure 6E).
METH preconditioning had no effect on the levels of
either MnSOD or CuZnSOD, but increased Bcl-2
Previous studies on preconditioning related to ischemia suggest
that mild oxidative stress is a perquisite for preconditioning and
that antioxidant enzymes are upregulated in response to oxidative
stress [9,18,50]. As noted above, there is also increasing evidence
that METH causes neurotoxicity by increasing the generation of
ROS. Based on these findings, we hypothesized that the
concentrations of METH that caused preconditioning also caused
a mild oxidative stress and that this might have stimulated an
counter-regulatory increase in antioxidative capacity; indeed, such
an observation would be consistent with in vivo findings [51], as
well as the findings from our lab in which MG132 was used in
conjunction with 6-OHDA in PC12 cells [9].
To test our hypothesis, we used Western blot analysis to
examine the change in the levels of two key antioxidant enzymes,
MnSOD and CuZnSOD after METH preconditioning. However,
we observed that 24 hr after METH treatment (0.5 mM), there
was no change in the levels of either MnSOD or CuZnSOD
(Fig. 7A).
We also examined Bcl-2, an anti-apoptotic protein whose
expression is up-regulated in response to mild stress [52,53]. Bcl-2
has also been found to protect against METH-induced toxicity
[54]. After 24 hr exposure to 0.5 mM METH, we observed a
significant 28% up-regulation of this protein (Fig. 7B), Inhibition
of the ERK and Akt pathways decreases Bcl-2 expression levels in
Figure 6. METH preconditioning enhanced Akt but not JNK activation in response to 6-OHDA. MN9D cells were treated with a sub-lethal
concentration of METH for 24 hr and then exposed to 100 mM 6-OHDA for 20 min before the cells were lysed at 15 min, 30 min, 1 hr, 6 hr, and 24 hr
post 6-OHDA. (A) METH decreased pAkt levels as shown for the 15 and 30 min time points. (B) METH preconditioning potentiates Akt activation in
response to 6-OHDA and no effect was seen on total Akt levels. (C) Quantification of pAkt compared to total Akt in 4 independent experiments. (D, E)
METH preconditioning has no effect on basal or 6-OHDA induced phosphorylation of JNK. a-tubulin was used to control for protein loading. Data are
means 6 SEM (N= 3). *p,0.05 compared to control.
doi:10.1371/journal.pone.0024722.g006
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the cells by 55% and 20% respectively. However, Bcl-2 expression
level was only decreased by 25% when the cells were
preconditioned for 24 hrs with 0.5 mM METH prior to U0126
treatment.
Discussion
Oxidative stress is widely implicated in neuronal cell death
associated with several neurodegenerative disorders, including PD,
Figure 7. Effect of METH preconditioning on MnSOD, CuZnSOD, and Bcl-2 levels. (A) MN9D cells were treated with 0.5 mM METH for 24 hr
and the cells lysates were analyzed for MnSOD, CuZnSOD, and Bcl-2 levels using Western blot analysis. Densitometry analysis showed that METH
preconditioning did not affect MnSOD and CuZnSOD but significantly increases Bcl-2 levels. (B) METH increases Bcl-2 in basal conditions and in the
presence of the ERK1/2 inhibitor U0126 but has no effects on Bcl-2 levels if the cells are pretreated with the Akt inhibitor LY294002. a-tubulin used as
a loading control. Data are means 6 ESM (N=3). *p,0.05 compared to control.
doi:10.1371/journal.pone.0024722.g007
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Alzheimer’s disease, and Huntington’s disease, as well as cell death
following ischemic stroke [11],[55,56,57]. In this report, we have
examined the effect of METH exposure on the subsequent
vulnerability of DA neurons to oxidative stress induced by the DA
neurotoxin, 6-OHDA. We used the dopaminergic cell MN9D,
which recapitulates many features of DA neurons. We found that
high, toxic concentrations of METH intensified the decrease in
metabolic activity induced by 6-OHDA as shown by the WST-1
assay. However, we also observed that lower, sub-toxic concen-
trations of METH attenuated the decline in ATP levels and in
mitochondrial dehydrogenase activity, and prevented the nuclear
condensation normally seen after exposure to 6-OHDA. This
finding is consistent with many previous reports. For example,
METH has also been shown to induce a tolerance to the
neurotoxic effects of MDMA [58], other amphetamines
[59,60,61,62,63], methamphetamine [64] and MPTP oxidation
products [65,66] as well as to 6-OHDA in an animal model of PD
[67]. Moreover, preconditioning and cross-tolerance using several
different drugs have been shown in various in vitro models of the
DA deficiency seen in PD [19,20,53].
The role of Erk1/2, Akt and JNK in METH preconditioning
ERK1/2 has been shown to be activated in response to
oxidative stress and trophic factors in a concentration- and a time-
dependent manner and to be involved in both cell death and cell
survival [68,69,70,71,72,73]. In this study, 6-OHDA increased
ERK1/2 phosphorylation as early as 15 min post-exposure. It is
generally accepted that the early transient activation of ERK1/2
promotes cell survival by activating anti-apoptotic signaling
pathways [29,74]. We have previously shown that 6-OHDA
activates ERK1/2 in a biphasic manner and inhibition of the early
ERK1/2 peak exacerbates 6-OHDA toxicity, suggesting that early
activation of ERK is a self-protection response to the toxin [30]. In
our study METH pre-exposure significantly enhanced the
transient ERK1/2 activation in response to 6-OHDA, suggesting
that METH preconditioning is partially mediated through the
activation of ERK1/2, which would be consistent with many other
studies [75,76,77,78,79]. Such a role for ERK1/2 is further
supported by our observation that the MEK1/2 inhibitor U0126
blocked the protective effect of METH preconditioning.
Paradoxically, METH pre-conditioning reduced basal levels of
pERK1/2 as well as pMEK1/2, a direct ERK1/2 upstream
component. However, we also observed a METH-induced
decrease in the activity of PP2A, a protein phosphatase implicated
in ERK1/2 dephosphorylation. From these observations, we
conclude that METH inhibits both pMEK1/2 and PP2A with the
net result depending on the stress level in the cells. In our study,
the balance between these two regulators of ERK phosphorylation
resulted in a decrease in pERK1/2 under basal conditions but an
increase in pERK1/2 during heightened oxidative stress caused by
6-OHDA.
As in the case of ERK1/2, METH preconditioning decreased
pAkt levels at early time points while enhancing its response to 6-
OHDA. Akt activation has been reported in various precondi-
tioning paradigms [80,81]. The activation of Akt in our paradigm
may reflect two separate events or an inter-dependent activation of
the ERK1/2 and PI3K pathways, which have both been shown to
be triggered by the activation of the G-protein coupled receptors
and growth factors receptors in cells [82].
In addition to its well established role in the execution of
apoptosis [83], the JNK pathway is likely to be involved in the
neurodegenerative cascade and has been implicated in the loss of
DA neurons in PD [for review, see [84,85]. However, whereas
JNK phosphorylation has been reported involved in cell death and
survival, the role of JNK in the setting of ischemic preconditioning
is controversial with studies suggesting both a protective and
detrimental aspects of JNK activation [86,87]. METH precondi-
tioning had no effect on JNK phosphorylation in response to 6-
OHDA in our experiments suggesting that this pro-death pathway
is not involved in METH preconditioning.
Implication of the increase in Bcl-2 in preconditioning in
the absence of an increase in SOD isoforms
Antioxidant enzymes isoforms MnSOD and CuZnSOD, as well
as heat shock protein, have been implicated in preconditioning in
various diseases models [88], and it has been suggested that mild
oxidative stress may be a prerequisite for preconditioning
[9,18,20,50]. Thus, we predicted that mild oxidative stress would
increase SOD levels. However, no changes in either MnSOD or
CuZnSOD were detected 24 hr after pretreatment of MN9D
cells with low, sub-toxic concentrations of METH. It is possible,
of course, that change in one or both of these enzymes does
occur earlier and was missed in our single time point analysis,
or that other anti-oxidant defenses are stimulated by METH
preconditioning.
On the other hand, we did observe a large, significant increase
in the anti-apoptotic protein, Bcl-2. This protein has previously
been shown to decrease significantly following various toxic
regimens of METH [89],[54,90], and to be involved in various
other preconditioning paradigms [20,52,53]. Thus, both our own
findings and those previously reported by others suggest to us that
Bcl-2 up regulation by low levels of METH acts to thwart the
activation of pro-apoptotic pathways and to trigger the activation
of pro-survival pathways in order to ultimately protect cells against
higher levels of oxidative stress. We further suggest that this effect
may be independent of the Ras/ERK pathway since Bcl-2 levels
were increased in the presence of ERK1/2 inhibitor U0126 in
preconditioned cells although the drug reduced basal Bcl-2 levels
and in accordance with previous studies [90].
The significance of METH-induced inhibition of DAT
METH reduced the uptake of DA in MN9D cells, a finding
consistent with previous reports as we have noted above.
Therefore, it was possible that the uptake of 6-OHDA into
MN9D cells is similarly altered, and thus that a component of the
apparent protection we observed was due to a decrease in 6-
OHDA transport into the cells. Our observations did, indeed,
indicate that METH inhibited DAT. However, it is highly unlikely
that this alteration of DA transport activity due to METH
preconditioning can explain the entire reduction in the vulnera-
bility of the cells to 6-OHDA. First, in our studies of DA uptake
that were designed to most closely mimic the conditions of our
preconditioning experiments, these effects were both small and
transient. Pretreatment with METH reduced 6-OHDA uptake,
but only by 20% and even this could only be detected during the
initial 5 min of toxin exposure; no effect of METH on 6-OHDA
levels was seen at 15 and 20 min, periods during which we have
previously shown that 6-OHDA remains in the medium [34].
Second, although 6-OHDA uptake may have been somewhat
reduced, 6-OHDA toxicity as measured by cell loss was actually
exacerbated by high METH concentrations suggesting that 6-
OHDA was still getting into the cells at toxic levels even at the
highest METH concentrations. Third, 0.5 and 1 mM METH
decreased DA uptake to the same extent, whereas the protection
they provided against 6-OHDA toxicity was concentration-
dependent. Fourth, many of the effects of 6-OHDA on intra-
cellular signaling molecules, such as the increases in pERK, pAkt,
pMEK, were actually intensified by METH pretreatment despite
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the transient reduction in 6-OHDA uptake. In short, it seems that
under our experimental conditions 6-OHDA continues to be taken
up into the cells after a very short-lived METH-induced inhibition
of this process, which is in accordance with previous data showing
a reversible reduction of DA uptake in synaptosomes following
pretreatments with DA [91] or METH [92]. Indeed, given the
METH-induced reduction in 6-OHDA uptake, it seems likely that
all of effects of METH on the response of the MN9D cells to 6-
OHDA were actually significantly under-estimated.
How then might METH reduce the sensitivity of the cells
to 6-OHDA?
There is still much to be learned about how exposure to sub-
toxic concentrations METH protects MN9D cells against 6-
OHDA. However, our results suggest some general outlines of
such a mechanism. Bcl-2 exerts a protective effect on cells via its
capacity to prevent activation of pre-apoptotic stimuli, and to
activate ERK and Akt [92]. The levels of pERK, on the other
hand, are regulated by pMEK and PP2A. Both pERK and pMEK
are increased by the high levels of ROS generated by 6-OHDA
and we hypothesize that METH preconditioning shifts the
pMEK/PP2A response to 6-OHDA such that pERK levels are
increased and cell survival is thereby favored. This appears also to
involve both activation of Akt and an increase in Bcl-2 levels. This
general scheme for preconditioning of dopaminergic cells by mild
stress is similar to that proposed for other cells, be they from heart
[92,93], kidney [92,94], or hippocampus [95,96], in which the
stress response has been elicited through mild ischemic episodes. A
similar scenario has been suggested for protease activated
receptors (PAR) where the activation of PARs is involved in both
neurodegeneration and neuroprotection in the brain, depending
on the amplitude and the duration of agonist stimulation [97].
PARs are G-protein coupled receptors that regulate cellular
response to extracellular serine proteases, like thrombin, trypsin,
and trypase. These studies reveal that the MAPK plays a critical
role in PAR-mediated neuroprotection suggesting that both cell
death and cell survival may share initial signaling proteins, but
differences in the amplitude as well as the duration of the signal
may result in finally opposite consequences [98]. PAR precondi-
tioning was shown in several animal models of neurodegenerative
diseases. For example, it has been shown that thrombin activated
PAR-1 can be protective in a rat 6-OHDA model, reducing both
neurological deficits and DA terminal loss [15,99]. Thrombin
induced PAR-1 activation was also shown protective against
synuclein induced toxicity [100] and to attenuate Ab-induced cell
death of hippocampal neurons and astrocyte stellation [101]. The
role of prothrombin/thrombin-induced activation of PARs in
neuroprotection and neurodegeneration has been extensively
reviewed, and the mechanism by which high concentrations of
thrombin exacerbates brain damage while low concentrations of
thrombin rescue neural cells from death after various brain insults
has been described [102].
Whatever the precise mechanism of the effects that we have
presented, the results suggest that exposure to low levels of cellular
stress can reduce the vulnerability of DA neurons. This is
consistent with previous studies of preconditioning in models of
PD from our lab [9,20] and others [99] and may have implications
for the development of neuroprotective therapies. The ability to
generalize preconditioning across disease models suggests that
pharmacological activation of a protective stress response without
the extracellular stress per se can be used to protect against
neurodegeneration. On the other hand, the results also suggest
that higher levels of oxidative stress – including those caused by
high concentrations of amphetamines – increase the vulnerability
of DA neurons. This latter result may in turn have implications for
drug abuse as a risk factor for PD, a possibility that has been
suggested by others [64,103].
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